Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Regulus Therapeutics Inc. Company Profile

02:57 EDT 19th April 2014 | BioPortfolio

Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative new medicines based on microRNAs. Regulus is targeting microRNAs as a new class of therapeutics by working with a broad network of academic collaborators and leveraging oligonucleotide drug discovery and development expertise from its founding companies Alnylam Pharmaceuticals (Nasdaq:ALNY) and Isis Pharmaceuticals (Nasdaq:ISIS). Regulus is advancing microRNA therapeutics towards the clinic in several areas including hepatitis C infection, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus’ intellectual property estate contains both the fundamental and core patents in the field and includes over 600 patents and more than 300 pending patent applications pertaining primarily to chemical modifications of oligonucleotides targeting microRNAs for therapeutic applications. In 2008, Regulus entered into a major alliance with GlaxoSmithKline to discover and develop microRNA therapeutics for immuno-inflammatory diseases. In 2010, Regulus entered into a new collaboration with GlaxoSmithKline to develop and commercialize microRNA therapeutics targeting microRNA-122 for the treatment of Hepatitis C Viral infection. For more information, visit http://www.regulusrx.com.


News Articles [32 Associated News Articles listed on BioPortfolio]

Regulus forms a pharma alliance with Sanofi

Regulus Therapeutics has renewed its strategic pharma alliance with Sanofi to discover, develop, and commercialize microRNA therapeutics to focus on specific orphan disease and oncology targets. Regul...

Sanofi renews alliance with Regulus and ups investment by $10 million

US pharma company Regulus Therapeutics has renewed its strategic alliance with French drug major Sanofi to develop and commercialize microRNA therapeutics to focus on specific orphan disease and oncol...

Regulus Therapeutics begins dosing in Phase I study of hepatitis drug RG-101

US-based Regulus Therapeutics has started dosing of RG-101, a sGalNAc-conjugated anti-miR targeting microRNA-122 (miR-122), in healthy subjects in a Phase I clinical study.

Regulus Therapeutics initiates dosing of RG-101 in Phase I study

Regulus Therapeutics, a biopharmaceutical company, has initiated dosing of RG-101, a sGalNAc-conjugated anti-miR targeting microRNA-122 (miR-122), in healthy subjects in the Phase I clinical study.

Regulus Therapeutics' CEO Presents at 32nd Annual JPMorgan Healthcare Conference (Transcript)

Regulus Therapeutics Inc. (RGLS) 32nd Annual JPMorgan Healthcare Conference Call January 16, 2014 11:30 AM ET Executives Kleanthis G. Xanthopoulos – President and Chief Executive Officer...

Regulus Therapeutics Inc. - Product Pipeline Review - 2013

Recently added to the BioPortfolio report store, Regulus Therapeutics Inc. - Product Pipeline Review - 2013 is a new report from Global Markets Direct published on 2013-10-30. This 28-page report is...

Regulus' CEO Discusses Q4 2013 Results - Earnings Call Transcript

Regulus Therapeutics Inc. (RGLS) Q4 2013 Results Earnings Conference Call February 27, 2014 5:00 PM ET Executives Amy Conrad - Director, Investor Relations and Corporate Communications Kleanthis X...

Regulus renews strategic alliance with Sanofi to focus on orphan disease and oncology targets

Regulus Therapeutics has renewed its strategic alliance with Sanofi to discover, develop, and commercialize microRNA therapeutics to focus on specific orphan disease and oncology targets.

Drugs and Medications [0 Results]

None

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Whole-genome sequence of muju virus, an arvicolid rodent-borne hantavirus.

The complete genome sequence of Muju virus was determined from lung tissue samples of three royal voles (Myodes regulus) captured in Gangwon province in the Republic of Korea. Since few whole genome s...

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Regulus Therapeutics Inc.

Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative new medicines based on microRNAs. Regulus is targeting microRNAs as a new c...

More Information about "Regulus Therapeutics Inc." on BioPortfolio

We have published hundreds of Regulus Therapeutics Inc. news stories on BioPortfolio along with dozens of Regulus Therapeutics Inc. Clinical Trials and PubMed Articles about Regulus Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Regulus Therapeutics Inc. Companies in our database. You can also find out about relevant Regulus Therapeutics Inc. Drugs and Medications on this site too.

Search BioPortfolio:
Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record

Advertisement